Cited by 342SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsViral Infections and Outbreaks Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice

Open access

Zhao, Jincun, Zhao, Jingxian, Perlman, Stanley·2010·Journal of Virology

Open this paper in CoChat — free account

Abstract

A dysregulated innate immune response and exuberant cytokine/chemokine expression are believed to be critical factors in the pathogenesis of severe acute respiratory syndrome (SARS), caused by a coronavirus (SARS-CoV). However, we recently showed that inefficient immune activation and a poor virus-specific T cell response underlie severe disease in SARS-CoV-infected mice. Here, we extend these results to show that virus-specific T cells, in the absence of activation of the innate immune response, were sufficient to significantly enhance survival and diminish clinical disease. We demonstrated that T cells are responsible for virus clearance, as intravenous adoptive transfer of SARS-CoV-immune splenocytes or in vitro -generated T cells to SCID or BALB/c mice enhanced survival and reduced virus titers in the lung. Enhancement of the number of virus-specific CD8 T cells by immunization with SARS-CoV peptide-pulsed dendritic cells also resulted in a robust T cell response, earlier virus clearance, and increased survival. These studies are the first to show that T cells play a crucial role in SARS-CoV clearance and that a suboptimal T cell response contributes to the pathological changes observed in SARS. They also provide a new approach to SARS vaccine design.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/jvi.01049-10

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

IL-17 and th17 cells
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, M. J. S., Lai, S., Poon, L. L. M., Guan, Y., Yam, L., Lim, W., Nicholls, J. M., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,916
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C. S., Epstein, J. H., Wang, H., Crameri, G. S., Hú, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,571
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H., Bachmann, J., Emmerich, N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,316
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications
van Rooijen, N., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,763
MHC ligands and peptide motifs: first listing
Rammensee, H., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
T-cell quality in memory and protection: implications for vaccine design
Seder, R. A., Darrah, P. A., & Roederer, M. (2008) · Nature reviews. Immunology · doi:10.1038/nri2274 · Cited by 1,565
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688
Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10
Sun, J., Madan, R., Karp, C. L., & Braciale, T. J. (2009) · Nature Medicine · doi:10.1038/nm.1929 · Cited by 626

Show all 36 references

Sorted by citations

Items 201–300 of 342

Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response
Zornikova, K. V., Khmelevskaya, A. A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., & Efimov, G. A. (2022) · Communications Biology · doi:10.1038/s42003-022-04250-7 · Cited by 17
Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia
Markov, N. S., Ren, Z., Senkow, K. J., Grant, R. A., Gao, C. A., Malsin, E. S., Sichizya, L., Kihshen, H., Helmin, K. A., Jovisic, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01914-w · Cited by 19
Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2
Gao, A., Chen, Z., Amitai, A., Doelger, J., Mallajosyula, V. V. A., Sundquist, E., Pereyra, F., Carrington, M. N., Davis, M. M., Streeck, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102311 · Cited by 33
Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage
McBride, D. A., Kerr, M., Dorn, N. C., Ogbonna, D. A., Santos, E., & Shah, N. J. (2020) · EMJ Innovation · doi:10.33590/emjinnov/20-00203 · Cited by 18
Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development
Dakal, T. C. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152091 · Cited by 16
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals
Delmonte, O. M., Oguz, C., Dobbs, K., Myint‐Hpu, K., Palterer, B., Abers, M. S., Draper, D., Truong, M., Kaplan, I. M., Gittelman, R., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.12.011 · Cited by 17
Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination
Davenport, B., Morrison, T. E., Kedl, R. M., & Klarquist, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100195 · Cited by 15
A VLP-Based Vaccine Candidate Protects Mice against Japanese Encephalitis Virus Infection
Yang, L., Xiao, A., Wang, H., Zhang, X., Zhang, Y., Li, Y., Wei, Y., Liu, W., & Chen, C. (2022) · Vaccines · doi:10.3390/vaccines10020197 · Cited by 15
A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine
Adam, A., Shi, Q., Wang, B., Zou, J., Mai, J., Osman, S. R., Wu, W., Xie, X., Aguilar, P. V., Bao, X., et al. (2021) · Translational research · doi:10.1016/j.trsl.2022.06.004 · Cited by 19
DCs-based therapies: potential strategies in severe SARS-CoV-2 infection
Han, J., Sun, J., Zhang, G., & Chen, H. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.47706 · Cited by 16
Infection and immune response to porcine hemagglutinating encephalomyelitis virus in grower pigs
Mora-Díaz, J. C., Temeeyasen, G., Magtoto, R. L., Rauh, R., Nelson, W. M., Carrillo-Ávila, J. A., Zimmerman, J. J., Piñeyro, P. E., & Gimenez-Lirola, L. G. (2020) · Veterinary Microbiology · doi:10.1016/j.vetmic.2020.108958 · Cited by 15
The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19
Xu, G., Qi, F., Wang, H., Liu, Y., Wang, X., Zou, R., Yuan, J., Liao, X., Liu, Y., Zhang, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816745 · Cited by 16
Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine
Thames, A. H., Wolniak, K. L., Stupp, S. I., & Jewett, M. C. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00644 · Cited by 15
Virus-Induced CD8+ T-Cell Immunity and Its Exploitation to Contain the SARS-CoV-2 Pandemic
Federico, M. (2021) · Vaccines · doi:10.3390/vaccines9080922 · Cited by 13
Identification of T-Cell Epitopes Using a Combined In-Silico and Experimental Approach in a Mouse Model for SARS-CoV-2
Noam Erez, A., Achdout, H., Yahalom-Ronen, Y., Adutler‐Lieber, S., Bar‐On, L., Bar‐Haim, E., Politi, B., Vitner, E. B., Tamir, H., Melamed, S., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100502 · Cited by 14
Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia
Khan, A. A., Alahmari, A., Almuzaini, Y. S., Alamri, F. A., Alsofayan, Y., Aburas, A., Al‐Muhsen, S., Kerkhove, M. D. V., Yezli, S., Ciottone, G. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727989 · Cited by 14
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
Uraki, R., Imai, M., Ito, M., Yamayoshi, S., Kiso, M., Jounai, N., Miyaji, K., Iwatsuki‐Horimoto, K., Takeshita, F., & Kawaoka, Y. (2024) · npj Vaccines · doi:10.1038/s41541-023-00800-0 · Cited by 14
SARS-COV-2 infections in inborn errors of immunity: A single center study
Cousins, K. L., DeFelice, N., Jeong, S., Feng, J., Lee, A. S. E., Rotella, K., Sanchez, D., Jaber, F., Agarwal, S., Ho, H.-E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035571 · Cited by 13
T Cells in Viral Infections: The Myriad Flavours of Antiviral Immunity
Jagadeesh, A., Prathyusha, A. M. V. N., Sheela, G. M., & Bramhachari, P. V. (2020) · Springer eBooks · doi:10.1007/978-981-15-1045-8_9 · Cited by 13
T cell responses to SARS-CoV-2 in humans and animals
Mattoo, S.-U.-S., & Myoung, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1624-z · Cited by 13
Mechanistic insights from the review and evaluation of ayurvedic herbal medicines for the prevention and management of COVID-19 patients
Sarkar, P. K., & Mukhopadhyay, C. D. (2022) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2022.100554 · Cited by 16
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
mRNA-LNP vaccine-induced CD8+ T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies
Montoya, B., Melo‐Silva, C. R., Tang, L., Kafle, S., Lidskiy, P., Bajusz, C., Vadovics, M., Muramatsu, H., Ábrahám, E., Lipinszki, Z., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.019 · Cited by 14
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2
Taşlı, P. N., Gönen, Z. B., Kırbaş, O. K., Gökdemir, N. S., Bozkurt, B. T., Bayrakçı, B., Sağraç, D., Taşkan, E., Demir, S., Gürcan, N. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.824378 · Cited by 12
A mathematical model of protein subunits COVID-19 vaccines
Gholami, S., Korosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Craig, M., Ghaemi, M. S., Ooi, H. K., & Heffernan, J. M. (2023) · Mathematical Biosciences · doi:10.1016/j.mbs.2023.108970 · Cited by 12
T cell control of SARS-CoV-2: When, which, and where?
Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12
Harnessing Biomaterials to Amplify Immunity in Aged Mice through T Memory Stem Cells
Hasani‐Sadrabadi, M. M., Majedi, F. S., Zárubová, J., Thauland, T. J., Arumugaswami, V., Hsiai, T. K., Bouchard, L., Butte, M. J., & Li, S. (2024) · ACS Nano · doi:10.1021/acsnano.3c08559 · Cited by 11
Nanovaccines to combat virus‐related diseases
Wu, F., Qin, M., Wang, H., & Sun, X. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1857 · Cited by 11
Antiviral effect of SARS-CoV-2 N-specific CD8+ T cells induced in lungs by engineered extracellular vesicles
Manfredi, F., Chiozzini, C., Ferrantelli, F., Leone, P., Pugliese, K., Spada, M., Virgilio, A. D., Giovannelli, A., Valeri, M., Cara, A., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00686-y · Cited by 12
Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19
Lee, P., & Kim, D.-J. (2020) · Immune Network · doi:10.4110/in.2020.20.e28 · Cited by 12
Investigation of immune cells on elimination of pulmonary‐Infected COVID‐19 and important role of innate immunity, phagocytes
Farshi, E., Kasmapur, B., & Arad, A. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2158 · Cited by 11
COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity
David, S., Dorado, G., Duarte, E. L., David-Bosne, S., Trigueiro-Louro, J. M., & Rebelo‐de‐Andrade, H. (2022) · Immunogenetics · doi:10.1007/s00251-022-01261-w · Cited by 13
Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics
Hoffman, M., Chigbu, D. I., Crumley, B. L., Sharma, R. K., Pustylnikov, S., Crilley, T. A., Ginwala, R., Loonawat, R., Joseph, J., Sales, D., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_1 · Cited by 10
The COVID-19 Vaccine Landscape
Koch, T., Fathi, A., & Addo, M. M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63761-3_31 · Cited by 11
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
Brunk, F., Moritz, A., Nelde, A., Bilich, T., Casadei, N., Fraschka, S. A. K., Heitmann, J. S., Hörber, S., Peter, A., Rammensee, H., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149290 · Cited by 10
Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia
Geronikolou, S. A., Takan, I., Pavlopoulou, A., Mantzourani, M., & Chrousos, G. P. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5090 · Cited by 10
Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine
Patel, R. S., & Agrawal, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952229 · Cited by 10
The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines
Lu, H., Xiao, J., Song, J., Song, Y., Li, H., Ren, H., Li, J., Cong, R., Li, H., Fang, Y., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70201 · Cited by 9
Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review
Tian, W., Ren, X., Han, M., Zhang, Y., Gao, X., Chen, Z., & Zhang, W. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221141802 · Cited by 9
Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation
Fishman, J. A., Roberts, M. B., Zhang, E. W., Kumar, D., Hirsch, H. H., & Maggiore, U. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc2004982 · Cited by 9
INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19
Velikova, T. V. (2021) · Central Asian Journal of Medical Hypotheses and Ethics · doi:10.47316/cajmhe.2021.2.1.05 · Cited by 9
Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis
Puzyrenko, A., Felix, J. C., Ledeboer, N. A., Sun, Y., Rui, H., & Sheinin, Y. M. (2021) · Pathology · doi:10.1016/j.pathol.2021.09.005 · Cited by 11
Human Coronaviruses: Counteracting the Damage by Storm
Schoeman, D., & Fielding, B. C. (2021) · Viruses · doi:10.3390/v13081457 · Cited by 8
Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities
Emadi‐Baygi, M., Ehsanifard, M., Afrashtehpour, N., Norouzi, M., & Joz-Abbasalian, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778913 · Cited by 8
Role of the cellular immunity in the formation of the immune response in coronavirus infections
Ia, I., Omelchenko, N. D., Filippenko, A. V., Trufanova, A. A., & Носков, А. К. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-rot-2302 · Cited by 11
The function of myeloid-derived suppressor cells in COVID-19 lymphopenia
Li, T., Zheng, F., & Cheng, F. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109277 · Cited by 8
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution
Li, L., Wei, Y., Han, Y., Yan, J., Li, X., Li, Z., Zhao, Y., Liang, H., & Wang, H. (2022) · Vaccines · doi:10.3390/vaccines10122035 · Cited by 8
Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes
Trujillo, J., Gras, S., Twist, K., Croft, N. P., Channappanavar, R., Rossjohn, J., Purcell, A. W., & Perlman, S. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400111 · Cited by 8
Self-citation
The conundrum of current anti-SARS-CoV-2 vaccines
Federico, M. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.03.001 · Cited by 7
Alveolar macrophages protect mice from MERS-CoV-induced pneumonia and severe disease
Channappanavar, R., Selvaraj, M., More, S., & Perlman, S. M. (2022) · Veterinary Pathology · doi:10.1177/03009858221095270 · Cited by 7
Self-citation
Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein
Manfredi, F., Chiozzini, C., Ferrantelli, F., Leone, P., Giovannelli, A., Sanchez, M., & Federico, M. (2022) · Vaccines · doi:10.3390/vaccines10071060 · Cited by 7
Distorted TCR repertoires define multisystem inflammatory syndrome in children
Malik, A., Tóth, E. N., Teng, M. S., Hurst, J. M., Watt, E., Wise, L., Kent, N., Bartram, J. L., Grandjean, L., Dominguez‐Villar, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274289 · Cited by 8
Vitamin D, infections and immunity
Misiorowski, W. (2020) · Wiedza Medyczna · doi:10.36553/wm.55 · Cited by 7
Aging Compromises Terminal Differentiation Program of Cytotoxic Effector Lineage and Promotes Exhaustion in CD8 + T Cells Responding to Coronavirus Infection
Zhu, Z., Lou, G., Luo, Y., Yihunie, K. D., Hoar, J., Daniel, J., Evers, B. M., Yao, C., & Wu, T. (2025) · Aging Cell · doi:10.1111/acel.70109 · Cited by 6
The effect of age on the magnitude and longevity of Th1‐directed CD4 T‐cell responses to SARS‐CoV ‐2
Nattrass, R. G., Krafft, L., Zjablovskaja, P., Schuster, M., Kasmapour, B., Sarisoy, C., Minich, J., Bach, E., & Streeck, H. (2022) · Immunology · doi:10.1111/imm.13475 · Cited by 4
Severely ill and high-risk COVID-19 patients exhibit increased peripheral circulation of CD62L+ and perforin+ T cells
Lesteberg, K. E., Araya, P., Waugh, K. A., Chauhan, L., Espinosa, J. M., & Beckham, J. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113932 · Cited by 7
Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV
Shahbaz, S., Sligl, W., Osman, M. S., & Elahi, S. (2023) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-023-00846-8 · Cited by 6
A REVIEW NOVEL CORONAVIRUS
Parameshwar, K., Pamu, S., Sandeep, K., & Suresh, C. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i4.36982 · Cited by 6
Clinical Features for Severely and Critically Ill Patients with COVID-19 in Shandong: A Retrospective Cohort Study
Zhou, S., Xu, J., Sun, W., Zhang, J., Zhang, F., Zhao, X., Wang, X., Zhang, W., Yu, L., Ning, K., et al. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s280079 · Cited by 6
Self-citation
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
Hong, J., Jhun, H., Choi, Y.-O., Taitt, A. S., Bae, S., Lee, Y.-M., Song, C., Yeom, S. C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e8 · Cited by 6
Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein
Harbour, J. C., Lyski, Z. L., Schell, J. B., Thomas, A., Messer, W. B., Slifka, M. K., & Nolz, J. C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100054 · Cited by 6
Immune responses to human respiratory coronaviruses infection in mouse models
Zhuang, Z., Liu, D., Sun, J., Li, F., & Zhao, J. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.015 · Cited by 6
Self-citation
Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
Chang, A., & Yu, J. (2022) · Viruses · doi:10.3390/v14020380 · Cited by 6
A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunityPreprint
Adam, A., Shi, Q., Wang, B., Zou, J., Mai, J., Osman, S. R., Wu, W., Xie, X., Aguilar, P. V., Bao, X., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.22.469576 · Cited by 6
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS ‐ CoV ‐2 in Exposed Individuals From Emilia Romagna Region and COVID ‐19 Severity
Mazzotti, L., de Souza, P. B., Azzali, I., Angeli, D., Nanni, O., Sambri, V., Semprini, S., Bravaccini, S., Cerchione, C., Gaimari, A., et al. (2025) · HLA · doi:10.1111/tan.70011 · Cited by 5
HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review
El‐Baky, N. A., Amara, A. A. A. F., & Redwan, E. M. M. M. (2023) · Vaccines · doi:10.3390/vaccines11030548 · Cited by 7
Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine
Qiu, S., Chen, Z., Zhu, A., Zeng, Q., Liu, H., Liu, X., Ye, F., Jin, Y., Wu, J., Yang, C., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01345-3 · Cited by 5
Self-citation
Increased Pathogenicity and Virulence of Middle East Respiratory Syndrome Coronavirus Clade B In Vitro and In Vivo
Wang, Y., Sun, J., Li, X., Zhu, A., Guan, W., Sun, D.-Q., Gan, M., Niu, X., Dai, J., Zhang, L., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00861-20 · Cited by 5
Self-citation
T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients
Luo, L., Chen, Q., Han, X., Shen, M., Hu, C., Chen, S., Zhang, J., Wang, Y., Li, T., Huang, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696662 · Cited by 5
Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine
Brian, C., Makrinos, D. L., Burke, H., Bree, D., Haridas, R., Tonkiss, I., Bartsch, Y. C., Alter, G., Malley, R., & Besin, G. (2022) · Vaccines · doi:10.3390/vaccines10071069 · Cited by 5
Local SARS-CoV-2 Peptide-Specific Immune Responses in Lungs of Convalescent and Uninfected Human SubjectsPreprint
Goliwas, K. F., Wood, A. M., Simmons, C. S., Khan, R., Khan, S. A., Wang, Y., Berry, J. L., Athar, M., Mobley, J. A., Kim, Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21263042 · Cited by 6
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in JapanPreprint
Tanishima, M., Ibaraki, K., Kido, K., Nakayama, S., Ata, K., Nakamura, H., Shinmura, Y., Endo, M., Sonoda, K., Ueda, K., et al. (2022) · medRxiv · doi:10.1101/2022.06.28.22276794 · Cited by 5
Mechanistic inferences from clinical reports of SARS-CoV-2
Jenkins, M. M., McCaw, T. R., & Goepfert, P. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1769853 · Cited by 4
Single-cell analysis reveals T cell dysfunction driven by macrophages and differential expression of transposable elements in severe COVID-19 patients
Zhu, A., Zhou, L. F., Chen, Z., Liu, D., Feng, H., Cai, B., Chen, X., Zhao, J., Zhao, J., Chen, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38688 · Cited by 4
Self-citation
Serum proteome reveals distinctive molecular features of H7N9- and SARS-CoV-2-infected patients
Wang, Y., Song, Z., Ran, P., Hang, X., Xu, Z., Xu, N., Deng, M., Zhu, L., Yin, Y., Feng, J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114900 · Cited by 4
Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges
Abdullahi, I. N., Emeribe, A. U., Adekola, H. A., Abubakar, S. D., Dangana, A., Shuwa, H. A., Nwoba, S. T., Mustapha, J. O., Haruna, M., Olowookere, A. K., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1812313 · Cited by 5
COVID-19 in children: reasons for uneventful clinical course
Sweni, S., Meenakshisundaram, R., Senthilkumaran, S., & Thirumalaikolundusubramanian, P. (2020) · Korean Journal of Pediatrics · doi:10.3345/cep.2020.00801 · Cited by 4
SARS-CoV2 coronavirus: so far polite with children. Debatable immunological and non-immunological evidence
Alvez, F. L. (2020) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2020.05.003 · Cited by 4
A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host
Minakshi, R., Jan, A. T., Rahman, S., & Kim, J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.575404 · Cited by 4
T cell receptor repertoire signatures associated with COVID-19 severityPreprint
Park, J. J.-Y., Lee, K. A. V., Lam, S. Z., & Chen, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470640 · Cited by 4
COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response
Fayyad, D., Kelts, J. L., Nielson, T. H., Epelle, I. L., Monear, N. C., Strawn, M. T. G., Woerner, B. N., & Xhabija, B. (2022) · BioChem · doi:10.3390/biochem2020009 · Cited by 4
Substances of abuse and their effect on SAR-CoV-2 pathogenesis
Antwi, I., Watkins, D., Pedawi, A., Ghrayeb, A., de Vuurst, C. V., & Cory, T. J. (2023) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2023-0004 · Cited by 3
HOW PREPARED ARE WE TO CONTROL SEVERE ACUTE RESPIRATORY SYNDROME IN FUTURE
Bhardwaj (2013) · Current Research in Virology · doi:10.3844/ajvsp.2013.8.19 · Cited by 3
Measurement of CD8 and CD4 T Cell Responses in Mouse Lungs
Fett, C., Zhao, J., & Perlman, S. M. (2014) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1083 · Cited by 3
Self-citation
The Role of Vitamin D in the Restriction of the Progress and Severity of COVID-19 Infection
Bharali, A., Deka, B., Sarma, H., Ahmed, A., Bhattacharjee, B., Sarma, S., Kumar, S., Kushari, S., & Devi, R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106980 · Cited by 2
Differential Kinetics of T Cell and Antibody Responses Delineate Dominant T Cell Epitopes in Long-Term Immunity after COVID-19Preprint
Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3713528 · Cited by 2
A burns and COVID-19 shared stress responding gene network deciphers CD1C-CD141- DCs as the key cellular components in septic prognosis
Liang, Q., Wang, L., Xu, J., Lin, A., Wu, Y., Tao, Q., Zhang, B., Min, H., Song, S., & Gao, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01518-7 · Cited by 2
Lung-resident SARS-CoV-2 peptide-specific immune responses in perfused 3D human lung explant models
Goliwas, K. F., Wood, A. M., Simmons, C. S., Khan, R., Khan, S. A., Wang, Y., Ramachandran, R., Berry, J. L., Athar, M., Mobley, J. A., et al. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1587080 · Cited by 2
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
Mestiri, S., Merhi, M., Inchakalody, V. P., Taib, N., Smatti, M. K., Ahmad, F., Raza, A., Ali, F. H., Hydrose, S., Fernandes, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1061255 · Cited by 2
Severe Acute Respiratory Syndrome Associated Corona Virus [SARS-CoV]
Akshay, P. S., Veena, S., Teja, K. B., & Tomar, S. J. (2023) · Springer eBooks · doi:10.1007/978-981-99-2820-0_5 · Cited by 2
IFN-γ decreases PD-1 in T lymphocytes from convalescent COVID-19 patients via the AKT/GSK3β signaling pathway
Song, M., Liu, X., Shen, W., Wang, Z., Wu, J., Jiang, J., Liu, Y., Xu, T., Bian, T., Zhang, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55191-6 · Cited by 3
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant
Uraki, R., Kiso, M., Ito, M., Yamayoshi, S., Halfmann, P., Jain, S., Suthar, M. S., Lopes, T. J. S., Jounai, N., Miyaji, K., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105794 · Cited by 2
Severe acute respiratory syndrome coronavirus
Hui, D. S., & Lee, N. L. S. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009915 · Cited by 2
SARS coronavirus infections of the lower respiratory tract and their prevention
Petrovsky, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804543-5.00003-8 · Cited by 2
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation
Glueck, O., Liang, X., Badell, I., Wratil, P. R., Graf, A., Krebs, S., Blum, H., Hellmuth, J. C., Scherer, C., Hollaus, A., et al. (2023) · Infection · doi:10.1007/s15010-023-02116-6 · Cited by 2
Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans
Watson, M. E., Inagaki, K., & Weinberg, J. B. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-21-000011 · Cited by 3
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model
Jiang, S., Wu, S., Zhao, G., He, Y., Bao, L., Liu, J., Qin, C., Hou, J., Ding, Y., Cheng, A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2016201 · Cited by 2
The T cell receptor repertoire reflects the dynamics of the immune response to vaccinationPreprint
Mohammed, K., Meadows, A., Hekmaty, S., Hatem, S., Simon, V. R., Jayaprakash, A. D., & Sachidanandam, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471735 · Cited by 2
Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013–2017
Tan, S., Gutiérrez, A. H., Gauger, P. C., Opriessnig, T., Bahl, J., Moise, L., & Groot, A. S. D. (2021) · Vaccines · doi:10.3390/vaccines9050468 · Cited by 1
How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery
Hajihasani, M. M., Farkhad, N. K., Mahmoudi, A. A., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230918092749 · Cited by 1

Authors: Zhao, J., Zhao, J., & Perlman, S.
Affiliations: University of Iowa (US)
Corresponding author: Perlman, Stanley
ORCID: Zhao, Jincun
Zhao, Jingxian
Perlman, Stanley
Venue: Journal of Virology
Publisher: American Society for Microbiology
Published: 2010-09-15
Volume: 84
Issue: 18
Pages: 9318-9325
ISSN: 0022-538X (ISSN-L)
1098-5514
DOI: 10.1128/jvi.01049-10
PMC: PMC2937604
OpenAlex: W1999546368
Cited by: 340
References: 36
Citations by year: 2026: 2 · 2025: 7 · 2024: 10 · 2023: 28 · 2022: 52 · 2021: 76 · 2020: 122 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 11 · 2015: 4 · 2014: 9 · 2013: 2 · 2012: 4
FWCI: 1.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Virology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (PO1AI060699, AI060699)
National Institute of Allergy and Infectious Diseases (R21AI079429, R56AI079429, P01AI060699)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
Keywords: SARS, SARS-CoV, T cell response, CD8+ T cells, viral clearance, adoptive T cell therapy, dendritic cell immunization, innate immune response, lung viral titers, SARS pathogenesis
MeSH terms: Animals, Lung, Mice, Inbred BALB C, Spleen, T-Lymphocytes, Viral Vaccines, Survival Analysis, Mice, SCID, Adoptive Transfer, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks